

# Gm9795 Promotes Inflammation in Non-Alcoholic Steatohepatitis via NF-κB/JNK Pathway by Endoplasmic Reticulum Stress

**Liangying Ye**

Guangzhou Medical University Second Affiliated Hospital <https://orcid.org/0000-0001-9721-2074>

**Dan Zhao**

Guangzhou Medical University Second Affiliated Hospital

**Yangzhi Xu**

Guangzhou Medical University Second Affiliated Hospital

**Jiaen Lin**

Guangzhou Medical University Second Affiliated Hospital

**Jiahui Xu**

Guangzhou Medical University Second Affiliated Hospital

**Kunyuan Wang**

Guangzhou Medical University Second Affiliated Hospital

**Zhanhui Ye**

Guangzhou Medical University Second Affiliated Hospital

**Yufeng Luo**

Guangzhou Medical University Second Affiliated Hospital

**Shiming Liu**

Guangzhou Medical University Second Affiliated Hospital

**Hui Yang (✉ [yanghui@gzmu.edu.cn](mailto:yanghui@gzmu.edu.cn))**

Guangzhou Medical University Second Affiliated Hospital <https://orcid.org/0000-0003-1344-501X>

---

## Research

**Keywords:** NAFLD, NASH, non coding RNA, Microarrays, ERS

**Posted Date:** November 13th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-106031/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on March 9th, 2021. See the published version at <https://doi.org/10.1186/s12967-021-02769-7>.

Gm9795 Promotes Inflammation in Non-Alcoholic Steatohepatitis via NF-κB/JNK Pathway by

Endoplasmic Reticulum Stress

Liangying Ye<sup>1\*</sup>, Dan Zhao<sup>1\*</sup>, Yangzhi Xu<sup>1\*</sup>, Jiaen Lin<sup>1</sup>, Jiahui Xu<sup>1</sup>, Kunyuan Wang<sup>1</sup>, Zhanhui Ye<sup>1</sup>, Yufeng Luo<sup>1</sup>, Shiming Liu<sup>2</sup>, Hui Yang<sup>1#</sup>

1. Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

2. Guangzhou Institute of Cardiovascular Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

\*Liangying Ye, Dan Zhao, Yangzhi Xu have equally contributed to this work

**#Contact information for corresponding author:** Hui Yang, yanghui@gzhmu.edu.cn

**Running title:** Gm9795 Promotes Inflammatory Response in NASH by ERS

**Abstract:**

**Background:** Non-alcoholic steatohepatitis (NASH) is a key stage in leading development of non-alcoholic simple fatty liver (NAFL) into cirrhosis and even liver cancer. This study aimed at exploring the lncRNA expression profile in NASH and the biological function of a novel lncRNA-gm9795.

**Methods:** Microarray analysis was performed to compare the expression profiles of lncRNAs in the liver of NASH, NAFLD and normal mice. Methionine-choline-deficient Medium(MCD) with Lipopolysaccharide(LPS) or palmitic acid(PA) were used to built NASH cell models. The role and mechanism of LncRNA-gm9795 in NASH were explored by knocking down or over-expressing its expression.

**Results:** A total of 381 lncRNAs were found to be not only highly expressed in NAFLD, but also is going to go even higher in NASH. A novel LncRNA-Gm9795 was significantly highly expressed in liver tissues of NASH animal models and NASH cell models. By staining with Nile red, we found that Gm9795 did not affect the fat accumulation of NASH. However, Gm9795 in NASH cell models significantly promoted the expression of TNF $\alpha$ , IL-6, IL-1 $\beta$ , the important inflammatory mediators in NASH. At the same time, we found that Gm9795 upregulated the key molecules in endoplasmic reticulum stress (ERS), while NF- $\kappa$ B/JNK pathways were also activated. When ERS activator Thapsigargin(TG) was introduced in cells with Gm9757 si-RNA, NF- $\kappa$ B and JNK pathways were activated. Conversely, ERS inhibitor Tauroursodeoxycholic(TUDCA) acid inhibited NF- $\kappa$ B and JNK pathways in cells with Gm9795 overexpression plasmid.

**Conclusion:** LncRNA-gm9795 promotes inflammatory response in NASH through NF- $\kappa$ B and JNK pathways by ERS, which might provide theoretical basis for revealing the pathogenesis of NASH and discovering new therapeutic targets

**Keyword:** NAFLD, NASH, non coding RNA, Microarrays, ERS

## **Background:**

Nowadays, non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world, and its estimated prevalence rate is 25% in the general population of Western and Asian countries[1, 2]. NAFLD refers to the accumulation of fat in the liver >5% per liver weight and the occurrence of diffuse hepatocyte bullae steatosis, in the presence of <10 g of daily alcohol consumption. The pathological process of NAFLD is mainly from non-alcoholic simple fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), and then to non-alcoholic cirrhosis (NAC) and even to liver cancer[3]. Among them, NASH is an extremely important pathological stage, and blocking the progression of NASH can effectively control the progression of NAFL to cirrhosis and liver cancer. However, the pathogenesis of the inflammatory response in NASH is not fully understood, leading to limited treatment options.

The specific pathogenesis of NAFLD is complex, and it has not yet reached a definite conclusion. One classical hypothesis of the pathogenesis of NAFLD is "two hit theory ". On the basis of the accumulation of lipid, oxidative stress caused by a variety of inflammatory cytokines (such as TNF $\alpha$ , IL-1, IL-6, etc.), and the release of fat factors (leptin, adiponectin, etc.), caused liver inflammation and liver cell damage, and eventually progressed to liver fibrosis[4]. Insulin resistance (Insulin to hold, IR) is the core link. However, this theory cannot fully explain the development of lipid deposition in liver cells during steatohepatitis, liver fibrosis and other NAFLD processes. In recent years, the theory of "multi hit" has emphasized the key role of Endoplasmic reticulum stress (ERS) in NAFLD, especially in NASH. Hypoxia, oxidative stress, exogenous substances, and the accumulation of unfolded proteins in the endoplasmic reticulum can all disrupt the endoplasmic reticulum balance, leading to ERS, liver lipid metabolism disorder, hepatocyte inflammatory necrosis and apoptosis, and ultimately the development of NASH[5, 6]. It is not difficult to notice the important role of inflammatory response and endoplasmic reticulum stress in NASH, so inhibiting inflammation and endoplasmic reticulum stress may be a strategy

for treating NASH.

Recent studies have shown that long noncoding RNAs (lncRNAs) play a key role in the regulation of gene expression, such as chromatin modification, transcription and post-transcriptional processing, and its abnormal expression is related to many physiological and pathological processes, such as embryonic development, cell proliferation and differentiation, steatosis, oxidative stress, endoplasmic reticulum stress, etc[7-10]. According to the data of multiple studies, there are thousands of differentially expressed lncRNAs in the liver of NAFLD, but only a few of them have been studied. Their role in fat metabolism in NAFLD has been mostly studied, while the role and regulatory mechanism of inflammation in NASH are poorly understood [11]. Therefore, the role of lncRNAs plays in the inflammation of NASH and its specific mechanism are worth studying. In conclusion, it is of great significance to explore the role of lncRNA in the occurrence and development of NSAH for finding reasonable and effective prevention and treatment measures. To explore the lncRNA expression profile in NAFLD and NASH, a microarray analysis was performed to compare the expression profiles of lncRNAs in the liver of NASH, NAFLD and normal mice. And we first found a key long non-coding RNA-gm9795, which is closely related to inflammation in NASH. So far, there have been no studies on LncRNA-gm9795. This study aims to explore the role of LncRNA-gm9795 in promoting inflammation in NASH and its molecular mechanism, so as to provide a theoretical basis for revealing the pathogenesis of NASH and discovering new therapeutic targets.

## **Materials and Methods:**

### **NASH Mouse model**

Male C57 BLKS/J db/db mice and C57 BLKS/J mice, 6 weeks old, each weighing 18–20 g, were purchased from Changzhou Cavens Laboratory Animal, Co., China. NASH mouse model was established by feeding C57 BLKS/J db/db mice with MCD diet for 4 weeks, NAFL mouse model was constructed by feeding C57 BLKS/J db/db mice with normal diet for 4 weeks, and C57 BLKS/J mice with normal diet as the control group[12]. After four weeks, all mice were sacrificed and their livers were removed. Liver tissues were used for RNA extraction for further detection.

### **RNA Preparation and Microarray Analysis**

Total RNA was extracted from the liver of NAFLD, NASH and control mice using Trizol and treated with DNase I (Invitrogen, Carlsbad, CA, United States). The integrity of RNA was assessed by electrophoresis on denatured agarose gel. Mouse LncRNA Microarray V2.0 (Arraystar, Rockville, MD, United States) was used to study the profiles of mouse lncRNAs and mRNA in the liver.

### **Cell culture**

AML 12 cells were purchased from the Cell Bank of Type Culture Collection (CBTCC, Chinese Academy of Sciences, Shanghai, China) and were cultured in DMEM/F12 (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, BI, Israel), 1% Insulin-Transferrin-Selenium(ITS, ScienCell, USA ), 0.2% Dexamethasone(DM, Sigma-Aldrich, USA) and 1% Penicillin-Streptomycin Solution(PS, Sigma-Aldrich, USA). Cells were maintained at 37 °C in a humidified 5% CO<sub>2</sub> atmosphere.

### **NASH cell model**

#### **MCD model:**

Spread AML12 cells on the six-hole plates at the density of 1.5×10<sup>5</sup>/ hole. After 24h, the

medium in the hole was discarded. 2ml of DMEM/F12 without FBS was added to each hole for 12 hours to starve cells. After 12h, 2ml MCD (Gibco, Carlsbad, CA) with 10% FBS medium was added to MCD model group. In the normal control group, 2ml of DMEM/F12 with 10%FBS, 1% ITS, 0.2% DM and 1% PS was added to each hole. After 12h, the medium in MCD model group was sucked out of the hole and placed in a sterile 4ml centrifuge tube. Lipopolysaccharide(LPS) was added to make the working concentration to 1 $\mu$ g/ml and then refill the hole. The culture was continued for 12h.

**PA model:**

AML12 cells were placed in the six-well plates at the density of  $1.5 \times 10^5$ / well, and the medium was discarded after 24h. DMEM/F12 without FBS was added to each well for 12h to starve cells. After that, the control group was cultured with 2ml of DMEM/F12 with 10%FBS, 1% ITS, 0.2% DM and 1% PS, and the PA model group was stimulated with 2ml 1Mm PA lipid medium (50ml 1Mm PA lipid medium is make up of 6ml 2.13mg/ml PA, 5ml 220mg/ml Bovine serum albumin(BSA) and 39 ml DMEM/F12) for 24h[13].

**Small interfering RNA and plasmid transfection in vitro:**

Small interfering RNAs (siRNAs) against LncRNA-gm9795 (GCCTGCATCGGTATTGAADTDT) were constructed (Genepharma, Suzhou, China) and transfected into AML12 cells by using LipofectaminTM 3000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Full-length LncRNA-gm9795 sequence and Flag protein sequence were cloned into the expression vector pCMV (Vigene, Shandong, China), and transfected into AML12 cells according to the manufacturer's instructions.

**RNA extraction and quantitative real time RT-PCR (qRT-PCR):**

Total RNA was extracted from cells or tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed by using the PrimeScript RT Reagent Kit and SYBR Premix Ex Taq (TaKaRa, Dalian, China) following the manufacturer's instructions. The

specific primers used for qRT-PCR are as follow(5'-3'):gm9795(forward:CCCCTAGAGAC  
TTTATCGACTT,reverse:AGTGCAGCCAGGTCTAATTGT),TNF $\alpha$ (forward:GCCACCACGCT  
CTTCTGTCTA,reverse:GGGTCTGGGCCATAGAACTGAT),IL-1 $\beta$ (forward:GCAACTGTTCC  
TGAACTCAACT, reverse:ATCTTTGGGTCCGTCAACT),IL-6(forward:CTCCCAACAGA  
CCTGTCTATACT, reverse:CCATTGCACAACCTTTCTCA), $\beta$ -actin(forward:GTGCTATGTT  
GCTCTAGACTTCG,reverse:ATGCCACAGGATTCCATACC),GAPDH(forward:GTTGTCTC  
CTGCGACTTCA,reverse:GCCCTCCTGTTATTATGG),MALAT1(forward:GCAGCAGTTC  
GTGGTGAAGATAGG, reverse:TCGCCTCCTCCGTGTGGTTG),IRE1 $\alpha$ (forward:GCAGGCT  
GTGTCTTTACTATG,reverse:TATCAATTCACGAGCAATGACG),CHOP(forward:CTCCAG  
ATTCCAGTCAGAGTTC, reverse:ACTCTGTTCCGTTCTAGTT),BIP(forward:ATGATG  
AAGTTCACTGTGGTGG, reverse:CTGATCGTTGGCTATGATCTCC). qRT-PCR results were  
analyzed to obtain CT values of amplified products, and the data was analyzed by the  
2- $\Delta\Delta$ CTmethod.

### Nuclear and cytoplasmic RNA extraction

AML 12 cells were treated according to the manufacturer's instructions (Thermo Fisher Scientific) to obtain separate nuclear and cytoplasm parts. RNA extraction and quantitative real-time PCR were respectively conducted for nuclear and cytoplasm parts.

### NILE Red

After the different treatments, cells were fixed with 4% paraformaldehyde at 26°C for 15 min, and incubated for 15 min with 1  $\mu$ M Nile red dye working fluid (a hydrophobic dye that accumulates in lipid droplets). Thereafter, DAPI was added to stain the nucleus and the cells were examined by a confocal microscope (Carl Zeiss Company, Germany).

### Western blot

Total proteins were extracted from cells and Westernblot was carried out according to the instructions. Membranes were then incubated with primary antibody [IRE1 $\alpha$ (1:1000 ,CST),

NF-κB/p65(1:1000 ,CST), p-NF-κB/p65 (1:1000 ,CST), JNK (1:1000, Bimake), p-JNK(1:1000 ,CST), c-Jun(1:1000 ,CST), p-c-Jun (1:1000 ,CST), TNF $\alpha$ (1:1000 Abcam),  $\beta$ -actin(1:1000 ,CST), FLAG-tag(1:1000 ,CST)] according to the manufacturer's instructions. The ECL chemiluminescence system was used to detect the signals.

### **Statistical analysis**

All data are presented as means $\pm$ SD. Statistically significant differences were determined using a Student's t-test or the Mann-Whitney U test. Statistical analyses were performed using SPSSv.20(IBM SPSS, Chicago, IL, USA). Values of P<0.05 were considered significant.

## **Results:**

### **Expression Profifiles of lncRNAs and mRNAs in Mice With NAFLD and NASH**

To determine the expression profifiles of lncRNAs and mRNAs in mice with NAFLD and NASH, the Mouse LncRNA Microarray V2.0 (Arraystar, Rockville, MD, United States) were used. Pathological sections showed that fat accumulation was significantly increased in DB/DB mice fed with normal diet(NAFLD model) compared with the control group, while DB/DB mice fed with MCD diet(NASH model) showed significant inflammatory cell infiltration, indicating the success of the model building(Fig.1-A). The results of Microarray showed that a total of 3111 lncRNAs (1915 upregulated and 1196 downregulated) were difffferentially expressed between the NAFLD and control groups. There were 1394 upregulated lncRNAs and 1283 downregulated lncRNAs were found between the NASH and control groups(Fig.1-B). Venn analysis was performed on the differentially expressed lncRNAs in the three groups to find the common and unique lncRNAs in the three groups. Results shows that there are 63 lncRNAs changed in all the three groups(Fig.1-C).And The results of Series Cluster found that there are 381 lncRNAs were found to be not only highly expressed in NAFLD, but also is going to go even higher in NASH (Figure.1-D), which caught our attention. Among these genes, we focus on a novel lncRNA-gm9795 and has carried on the thorough research to it.

#### **LncRNA-gm9795 has no coding capacity and is located in the nucleus**

In order to further understand LncRNA-gm9795, we first studied its basic characteristics. With the method of separating nucleoplasm RNA, its expression in the nucleus and cytoplasm was detected. LncRNA - MALAT1 was recruited as the nucleus marker gene, while beta actin was used as the plasma marker gene. The results showed that LncRNA-gm9795 was mainly distributed in the nucleus all in the control group (Fig.2-A), MCD+LPS group (Fig.2-B) and PA group (Fig.2-C). And it tended to emerge from the nucleus to cytoplasm after modeling. Then we connected the full length of LncRNA-gm9795 with the FLAG sequence to construct plasmids.

The expression of FLAG tag was detected after the transfection into normal mouse liver cells, and Actin connected with the FLAG sequence was used as the positive control. The results showed that the expression of FLAG tag could be detected by the transfection of Actin-Flag, while the expression of FLAG tag was not detected by the transfection of LncRNA-gm9795-FLAG(Fig.2-D).

### **LncRNA-gm9795 is highly expressed in liver tissues of NASH mouse and cell models**

MCD medium combined with 1  $\mu$ g/ml LPS and 1 mM PA were used to stimulate AML12 cells and primary mouse liver cells to construct NASH in vitro model, and the mRNA expression level of LncRNA-gm9795 in vitro model was verified by RT-qPCR. Similarly, LncRNA-gm9795 increased about 5 times in the MCD+LPS AML12 cell model (Fig.2-E) and 2 times in the PA AML12cell model (Fig.2-F), and the results were also validated in the NASH model of primary hepatocytes (Fig2-G&H) ( $P<0.05$ ).Meanwhile, We used male C57 BLKS/J db/db mice with normal and MCD diet to construct mouse models of NAFL and NASH respectively, with C57 BLKS/J mice feeding normal diet as the control group. RNA was extracted from the liver tissues of mice in each group and the expression of LncRNA-gm9795 was detected by qRT-qPCR. The results showed that the mRNA level of LncRNA-gm9795 in NASH liver tissues was about 6 times higher than that in normal liver tissues (Fig.2-I).

### **LncRNA-gm9795 does not affect fat accumulation in NASH**

In order to determine whether LncRNA-GM9795 affects lipid accumulation during the pathogenesis of NASH, MCD+LPS and PA were respectively constructed NASH model after interfering LncRNA-GM9795 in normal AML12, and the lipid deposition was observed in cells by fluorescent imaging using Nile red staining.Fluorescence imaging showed that the red fluorescence increased after the MCD+LPS and PA model was constructed, indicating that the lipid deposition increased. However, the interference with lncRNA-GM9795 did not decrease the red fluorescence (FIG.3-A&B).Similar phenomena can be observed with over-expression of

LncRNA-GM9795((FIG.3-C)).

**LncRNA-gm9795 significantly increases the expression of inflammation factors in NASH through NF-kB/JNK pathway**

The expression of LncRNA-gm9795 in normal mouse liver cells-AML12 was interfered with siRNA in two NASH models. The interference efficiency and the mRNA expression of inflammatory factors TNF $\alpha$ , IL-6 and IL-1 $\beta$  were detected by qPCR. Western blot was used to detect the protein expression of the above factors. Results showed that LncRNA-gm9795 was downregulated effectively (Fig.4-A&E), and the mRNA expression of TNF $\alpha$ , IL-6 and IL-1 $\beta$  was reduced when silencing the expression of LncRNA-gm9795 (Fig.4-B-D&F-G). Western Blot results showed that the expression of TNF $\alpha$ , IL-6 and IL-1 $\beta$  in both the two NASH models was increased, and their expression was significantly decreased after interfering with LncRNA-gm9795(Fig.4-I&J).

To further understand its biological function. the LncRNA-gm9795 overexpression plasmid was transfected into AML12 cells. Two NASH models were respectively constructed with MCD+LPS and PA. The overexpress efficiency and the expression of inflammatory factors were detected by qPCR, and the protein levels were detected by Western Blot. After the transfection with LncRNA-gm9795 overexpression plasmid, the mRNA level of gm9795 in AML12 cells was increased by more than 150 times (Fig.5-A), which proved that the transfected plasmid was successful. TNF $\alpha$ , IL-6 and IL-1 $\beta$ mRNA level in the overexpression group was about 3 times higher than that in the normal control group by qPCR (Fig.5-B-D). Western Blot results showed that the expression of inflammation factors was significantly up-regulated in the overexpression group (Fig.5-E).

Inflammatory response is an important link in NASH. After changing the expression of LncRNA gm9795, the protein levels of classic inflammatory pathway proteins NF-kB/p65, JNK and c-Jun were detected by Western Blot. Results showed that the expression of NF-kB/p65,

p-NF-kB/p65, JNK, p-JNK, c-Jun and p-c-Jun in both the two NASH model were increased, and the expression levels of the above proteins were significantly decreased after interfering with LncRNA-gm9795 (Fig.6-A&B). LncRNA-gm9795 overexpression plasmid was transfected into AML12 cells Western Blot results showed that the expression of p-NF-kB/p65, p-JNK, c-Jun and p-c-Jun was significantly up-regulated in the overexpression group (Fig.6-C). Thus, it is clear that LncRNA gm9795 up-regulated inflammation factors expression by activating NF-kB/JNK signaling pathway.

#### **LncRNA-gm9795 activates NF-kB/JNK pathway by activating ERS**

ERS, as the current studies say, is an important part of the evolution of NASH. Thus, the expression of ERS-related molecules in the NASH models with LncRNA-gm9795 overexpression and knockout was detected. Results showed that after LncRNA-gm9795 was knocked out, the expression of IRE1 $\alpha$  and Bip was down-regulated, while no significant change was observed in CHOP (Figure7). qPCR and Western Blot results also showed that the expression of IRE1 $\alpha$  and Bip was significantly up-regulated in the overexpression group(Figure7).

To determine whether LncRNA-gm9795 up-regulates the inflammatory factors by activating NF-kB/JNK signaling pathway through ERS, after interfering with LncRNA-gm9795, MCD+LPS and PA were used to establish NASH models, and endoplasmic reticulum stress agonist Thapsigargin (Tg) (800nM) was added to stimulate the models for 24h. Western Blot showed that the addition of Tg could significantly reverse the effect of interfering LncRNA-gm9795 on the proteins of the IRE1 $\alpha$  /NF-kB /p65/JNK pathway (Fig.8-A &B) . At the same time, we transfected LncRNA-gm9795 overexpression plasmid into AML12 cells and added the endoplasmic reticulum stress inhibitor TUDCA (0.2mm) to stimulate them for 24h after transfection. Western Blot showed that TUDCA could antagonize the up-regulation of IRE1 $\alpha$ /NF-kB /JNK pathway caused by the overexpression of LncRNA-gm9795(Fig.8-C).

## DISCUSSION

In recent years, LncRNA has attracted more and more attentions. Studies have shown that lncRNA plays a key role in regulating gene expression such as chromatin modification, transcription and post-transcriptional processing, and its abnormal expression is related to many physiological and pathological processes, such as embryonic development, cell proliferation and differentiation, steatosis, oxidative stress, endoplasmic reticulum stress, etc[14, 15]. One of the first investigations of lncRNAs in NAFLD fibrosis demonstrated that MEG3 expression was decreased in livers from CCl4-treated mice compared to oil-fed control mice, and Meg3 expression diminished concordantly with the progression of fibrosis[16]. In an independent study, Aptr expression was found to be more than twofold higher in fibrotic livers of two animal models for liver fibrosis (CCl4 and bile duct ligation (BDL) mice) and in humans with liver fibrosis of undisclosed etiology[17]. And hepatic Malat1 expression was upregulated in hepatic stellate cells and hepatocytes respectively isolated from CCl4-treated animals when compared to control mice[18]. There's no doubt that lncRNAs play an important role in NASH. Our study found a new lncRNA-gm9795, which is specifically high expressed in NASH. It is consistent with the results of our previous gene chip. We found through experiments that the lncRNA had no coding ability and was mainly distributed in the nucleus. It lays a solid foundation for us to further study its functions.

The specific pathogenesis of NAFLD is complex, and no definite conclusion has been reached by domestic and foreign scholars. Both the two hypothesis of NAFLD emphasized inflammation in NASH[19]. The accumulation of a variety of inflammatory cytokines (such as TNF $\alpha$ , IL-1, IL-6, etc.) causes liver inflammation and liver cell damage, and then progresses to liver fibrosis [20]. The present study found that LncRNA-gm9795 up-regulates the expression of inflammatory cytokines in NASH, in both the NASH in vitro models, indicating that LncRNA-gm9795 promotes inflammatory reaction in NASH.

In recent years, the "multiple hit" theory highlights the key role of ER stress in NAFLD, especially in NASH[21]. Endoplasmic reticulum (ER) is the site of protein synthesis, folding, transit and modification. ER is extremely sensitive to various stimuli, including hypoxia, hyperglycemia, chemical poisons and other factors, which may lead to the accumulation of misfolded and unfolded proteins in the lumen of ER and causing ERS. The first reaction occurs in ERS is that the up-regulation of molecular chaperone glucose regulating protein 78 (GRP78) improves protein folding or corrects misfolding. However, the binding of GRP78 and unfolded proteins results in its dissociation with the stress sensor protein kinase RNA-like endoplasmic reticulum kinase (PERK) and inositol requiring enzyme 1 $\alpha$  (IRE1 $\alpha$ ), which causes the activation of these proteins and triggers ERS. After the dissociation of PERK with GRP78, PERK is activated by dimerization and autophosphorylation, which phosphorylates the downstream factor eukaryotic translation initiation factor 2 $\alpha$  (EIF2 $\alpha$ ), thereby forming P-EIF2 $\alpha$ . P-EIF2 $\alpha$  regulates the activation of NF- $\kappa$ B via reducing the synthesis of the inhibitor of NF- $\kappa$ B (I $\kappa$ B)[22-24]. Therefore, ERS-related inflammation plays an important role in the development of insulin resistance, liver injury, and hepatic fibrosis in NASH. Our study found that LncRNA-gm9795 in NASH in vitro model significantly activates the expression of IRE1 $\alpha$  and BIP, which are key molecules of endoplasmic reticulum stress. However, CHOP, an important pro-apoptotic molecule in ERS, did not change significantly. We assume that gm9795 does not affect apoptosis in NASH. Furthermore, the NF- $\kappa$ B/JNK pathway related proteins were also found activated. And we found that it can be restored by an agonist or inhibitor of ERS. It means LncRNA-gm9795 might activate NF- $\kappa$ B/JNK pathway by activating ERS, finally resulting in inflammation. It would be a new finding in the development of NASH, which might provide a new therapeutic target.

### **Conclusion:**

The present study found a novel LncRNA-gm9795, which was significantly up-regulated in

vivo and in vitro models. The abnormal high expression of LncRNA-gm9795 could enhance ERS, activate the signaling pathway of NF- $\kappa$ B /JNK, and subsequently affect the expression of inflammatory factors. These findings help us better understand the various mechanisms of LncRNA-gm9795, which may become a potential prognostic indicator and therapeutic target for NASH.

**List of abbreviations:**

|       |                                     |
|-------|-------------------------------------|
| ITS   | Insulin-Transferrin-Selenium        |
| DM    | Dexamethasone                       |
| MCD   | Methionine-choline-deficient Medium |
| LPS   | Lipopolysaccharide                  |
| PA    | Palmitic acid                       |
| ERS   | Endoplasmic reticulum stress        |
| TG    | Thapsigargin                        |
| TUDCA | Tauroursodeoxycholic                |



## **Declarations**

### **Ethics approval and consent to participate:**

All institutional and national guidelines for the care and use of laboratory animals were followed.

The animal studies were approved by the Ethics Committee of the Second Affiliated Hospital, Guangzhou Medical University. Not applicable for human data or tissue.

### **Consent for publication:**

Not applicable.

### **Availability of data and materials:**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### **Competing interests:**

The authors declare that they have no competing interests.

### **Funding:**

This work was supported by the National Natural Science Foundation of China (no. 81372634), Key projects of universities of Guangdong Province Office of Education (no. 2019KZDXM006), Youth Fund Projects of Basic and Applied Basic Research of Guangdong Province (no. 2019A1515110081 and no. 2019A1515110652) and Young Talents Program of Guangzhou Education Bureau (no. 201831831).

### **Author contributions:**

Hui Yang, Yangzhi Xu were involved in study design; Liangying Ye, Dan Zhao performed the experiments; Jiaen Lin, Jiahui Xu, Kunyuan Wang analyzed data; Zhanhui Ye, Yufeng Luo, Shiming Liu commented on the manuscript; Hui Yang, Liangying Ye, Dan Zhao and Yangzhi Xu supervised the study and wrote the paper. All authors read and approved the final manuscript.

### **Acknowledgements:**

Not applicable.

### **References:**

- [1] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *HEPATOLOGY* 2016;64:73.
- [2] Wong SW, Chan WK. Epidemiology of non-alcoholic fatty liver disease in Asia. *Indian J Gastroenterol* 2020.
- [3] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. *CELL MOL LIFE SCI* 2019;76:99.
- [4] Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". *World J Gastroenterol* 2018;24:2974.
- [5] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *METABOLISM* 2016;65:1038.
- [6] Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. *Free Radic Res* 2015;49:1405.
- [7] Chi Y, Gong Z, Xin H, Wang Z, Liu Z. Long noncoding RNA lncARSR promotes nonalcoholic fatty liver disease and hepatocellular carcinoma by promoting YAP1 and activating the IRS2/AKT pathway. *J TRANSL MED* 2020;18:126.
- [8] Chen Y, Chen X, Gao J, Xu C, Xu P, Li Y, Zhu Y, Yu C. Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway. *FASEB J* 2019;33:11411.
- [9] Takahashi K, Yan I, Haga H, Patel T. Long noncoding RNA in liver diseases. *HEPATOLOGY* 2014;60:744.
- [10] Wang H, Cao Y, Shu L, Zhu Y, Peng Q, Ran L, Wu J, Luo Y, Zuo G, Luo J, Zhou L, Shi Q, Weng Y, Huang A, He TC, Fan J. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes. *J CELL MOL MED*

2020;24:1399.

[11] Zhao Y, Wu J, Liangpunsakul S, Wang L. Long Non-coding RNA in Liver Metabolism and Disease: Current Status. *Liver Res* 2017;1:163.

[12] Chen X, Xu Y, Zhao D, Chen T, Gu C, Yu G, Chen K, Zhong Y, He J, Liu S, Nie Y, Yang H. LncRNA-AK012226 Is Involved in Fat Accumulation in db/db Mice Fatty Liver and Non-alcoholic Fatty Liver Disease Cell Model. *FRONT PHARMACOL* 2018;9:888.

[13] Mai W, Xu Y, Xu J, Zhao D, Ye L, Yu G, Wang Z, Lu Q, Lin J, Yang T, Gu C, Liu S, Zhong Y, Yang H. viaBerberine Inhibits Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation and Pyroptosis in Nonalcoholic Steatohepatitis the ROS/TXNIP Axis. *FRONT PHARMACOL* 2020;11:185.

[14] Barth DA, Prinz F, Teppan J, Jonas K, Klec C, Pichler M. Long-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer. *Noncoding RNA* 2020;6.

[15] Zottel A, Šamec N, Videtič PA, Jovčevska I. Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs. *Cancers (Basel)* 2020;12.

[16] Huang P, Huang FZ, Liu HZ, Zhang TY, Yang MS, Sun CZ. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. *METABOLISM* 2019;94:1.

[17] Makhmudi A, Supanji R, Putra BP, Gunadi. The effect of APTR, Fn14 and CD133 expressions on liver fibrosis in biliary atresia patients. *PEDIATR SURG INT* 2020;36:75.

[18] Leti F, Legendre C, Still CD, Chu X, Petrick A, Gerhard GS, DiStefano JK. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. *TRANSL RES* 2017;190:25.

[19] Gariani K, Jornayvaz FR. [NASH: a less known but severe complication of diabetes]. *Rev Med Suisse* 2020;16:1197.

[20] Lefere S, Devisscher L, Geerts A. Angiogenesis in the progression of non-alcoholic fatty

liver disease. Acta Gastroenterol Belg 2020;83:301.

[21] Lebeaupin C, Vallee D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J HEPATOL 2018;69:927.

[22] Wang L, Chen J, Ning C, Lei D, Ren J. Endoplasmic Reticulum Stress Related Molecular Mechanisms in Nonalcoholic Fatty Liver Disease (NAFLD). CURR DRUG TARGETS 2018;19:1087.


[23] Vallee D, Blanc M, Lebeaupin C, Bailly-Maitre B. [Endoplasmic reticulum stress response and pathogenesis of non-alcoholic steatohepatitis]. Med Sci (Paris) 2020;36:119.

[24] Jiang H, Guan Q, Xiao Y, Feng Z, Yu G, Pan Q. Strontium Alleviates Endoplasmic Reticulum Stress in a Nonalcoholic Fatty Liver Disease Model. J MED FOOD 2018.


## Figures and figure legends

**Fig.1**

**a**



**b**



**d**

Profiles ordered based on the number of genes assigned




Fig1. Profiles of lncRNAs in NAFLD, NASH and control mice: a. Pathological sections of liver of NAFLD, NASH, and control mice; b. Differences in lncRNAs between NAFLD, NASH and

control mice; c. The venn analysis of differential lncRNAs of NAFLD, NASH and control mice; d. The series cluster analysis of differential lncRNAs of NAFLD, NASH and control mice.

Fig.2




Fig2. LncRNA-gm9795 is highly expressed in liver tissues of NASH mice and cell models:  
a.LncRNA-gm9795 mainly in the nucleus in control group; b. LncRNA-gm9795 mainly in the nucleus in MCD+LPS group; c.LncRNA-gm9795 mainly in [A group; d.Three Open Read Frames of LncRNA-gm9795 predicted in the database showed no coding capacity; e. LncRNA-gm9795 is highly expressed in NASH cell models built by MCD+LPS in AML12; f. LncRNA-gm9795 is highly expressed in NASH cell models built by PA in AML12; g. LncRNA-gm9795 is highly expressed in NASH cell models built by MCD+LPS in mouse primary hepatocytes; h. LncRNA-gm9795 is highly expressed in NASH cell models built by PA in mouse primary hepatocytes;i.LncRNA-gm9795 is highly expressed in NASH mouse models ;(NS: Nonsense, \*:P<0.05, \*\*P<0.01,\*\*\*P<0.001)

Fig.3




Fig3. lncRNA-gm9795 did not affect lipid accumulation in NASH: a. Fluorescence imaging shows there was no significant change in lipid deposition after interference with lncRNA-gm9795 in MCD+LPS model; b. Fluorescence imaging shows there was no significant change in lipid deposition after interference with lncRNA-gm9795 in PA model; c. Fluorescence imaging shows there was no significant change in lipid deposition after overexpressing lncRNA-gm9795 in MCD+LPS model; d. Fluorescence imaging shows there was no significant change in lipid deposition after overexpressing lncRNA-gm9795 in PA model;

**Fig.4**




Fig4. Knocking down LncRNA-gm9795 significantly decreased the expression of inflammation factors in NASH: a. Interference efficiency of siRNA-gm9795 in MCD+LPS model; b. In MCD+LPS model, the mRNA expression of TNF $\alpha$  was decreased after knocking down gm9795;c. In MCD+LPS model, the mRNA expression of IL-6 was decreased after knocking down gm9795; d. In MCD+LPS model, the mRNA expression of IL-1 $\beta$  was decreased after knocking down

gm9795; e. Interference efficiency of siRNA-gm9795 in PA model; f. In PA model, the mRNA expression of TNF $\alpha$  was decreased after knocking down gm9795; g. In PA model, the mRNA expression of IL-6 was decreased after knocking down gm9795; h. In PA model, the mRNA expression of IL-1 $\beta$  was decreased after knocking down gm9795; i. In MCD+LPS model, the protein expression of inflammation factors was decreased after knocking down gm9795; j. In PA model, the protein expression of inflammation factors was decreased after knocking down gm9795; (\*:P<0.05, \*\*P<0.01, \*\*\*P<0.001).

Fig.5




Fig5. LncRNA-gm9795 significantly increased the expression of inflammatory factors in NASH:  
a. The efficiency of gm9795 overexpression plasmid; b. The mRNA expression of TNF $\alpha$  increased after the overexpression of gm9795; c. The mRNA expression of IL-6 increased after the overexpression of gm9795; d. The mRNA expression of IL-1 $\beta$  increased after the overexpression of gm9795; e. The protein expression of inflammatory factors increased after the overexpression of gm9795; (\*:P<0.05, \*\*P<0.01, \*\*\*P<0.001).

**Fig.6**




Fig6. LncRNA-gm9795 significantly increased the expression of inflammation factors in NASH through NF- $\kappa$ B/JNK pathway: a. The expression of NF- $\kappa$ B/JNK signaling proteins was decreased after gm9795 knockout in MCD+LPS model; b. The expression of NF- $\kappa$ B/JNK signaling proteins was decreased after gm9795 knockout in PA model; c. The expression of NF- $\kappa$ B/JNK signaling proteins was increased after the overexpression of gm9795;

Fig.7




Fig7. LncRNA-gm9795 activates ERS: a. The mRNA expression of IRE1 $\alpha$  was decreased after gm9795 knockout in MCD+LPS model; b. The mRNA expression of BIP was decreased after gm9795 knockout in MCD+LPS model; c. The mRNA expression of CHOP had no significant change after gm9795 knockout in MCD+LPS model; d. The mRNA expression of IRE1 $\alpha$  was decreased after gm9795 knockout in PA model; e. The mRNA expression of BIP was decreased after gm9795 knockout in PA model; f. The mRNA expression of CHOP had no significant change after gm9795 knockout in PA model; g. The protein expression of ERS was decreased after gm9795 knockout in MCD+LPS model; h. The protein expression of ERS was decreased after gm9795 knockout in PA models; (NS: Nonsense, \*: $P<0.05$ , \*\*: $P<0.01$ , \*\*\*: $P<0.001$ )

**Fig.8**





Fig8. LncRNA-gm9795 activated NF-κB/JNK pathway through ERS:a. The NF-κB/JNK pathway was activated by introducing endoplasmic reticulum stress agonists after gm9795 was knocked out in MCD+LPS model; b. The NF-κB/JNK pathway was activated by introducing endoplasmic reticulum stress agonists after gm9795 was knocked out in PA model; c. The NF-κB/JNK pathway was inhibited by introducing endoplasmic reticulum stress inhibitor after gm9795 was overexpressed


# Figures



**Figure 1**


Profiles of lncRNAs in NAFLD, NASH and control mice: a. Pathological sections of liver of NAFLD, NASH, and control mice; b. Differences in lncRNAs between NAFLD, NASH and control mice; c. The venn analysis

of differential lncRNAs of NAFLD, NASH and control mice; d. The series cluster analysis of differential lncRNAs of NAFLD, NASH and control mice.



**Figure 2**


LncRNA-gm9795 is highly expressed in liver tissues of NASH mice and cell models: a. LncRNA-gm9795 mainly in the nucleus in control group; b. LncRNA-gm9795 mainly in the nucleus in MCD+LPS group; c. LncRNA-gm9795 mainly in the nucleus in PA group; d. Three Open Read Frames of LncRNA-gm9795 predicted in the database showed no coding capacity; e. LncRNA-gm9795 is highly expressed in NASH cell models built by MCD+LPS in AML12; f. LncRNA-gm9795 is highly expressed in NASH cell models built by PA in AML12; g. LncRNA-gm9795 is highly expressed in NASH cell models built by MCD+LPS in mouse primary hepatocytes; h. LncRNA-gm9795 is highly expressed in NASH cell models built by PA in mouse primary hepatocytes; i. LncRNA-gm9795 is highly expressed in NASH mouse models; (NS: Nonsense, \*: P<0.05, \*\*P<0.01, \*\*\*P<0.001)



**Figure 3**

lncRNA-gm9795 did not affect lipid accumulation in NASH: a. Fluorescence imaging shows there was no significant change in lipid deposition after interference with lncRNA-gm9795 in MCD+LPS model; b. Fluorescence imaging shows there was no significant change in lipid deposition after interference with lncRNA-gm9795 in PA model; c. Fluorescence imaging shows there was no significant change in lipid


deposition after overexpressing lncRNA-gm9795 in MCD+LPS model; d. Fluorescence imaging shows there was no significant change in lipid deposition after overexpressing lncRNA-gm9795 in PA model;



**Figure 4**


Knocking down lncRNA-gm9795 significantly decreased the expression of inflammation factors in NASH: a. Interference efficiency of siRNA-gm9795 in MCD+LPS model; b. In MCD+LPS model, the mRNA expression of TNF $\alpha$  was decreased after knocking down gm9795;c. In MCD+LPS model, the mRNA expression of IL-6 was decreased after knocking down gm9795; d. In MCD+LPS model, the mRNA expression of IL-1 $\beta$  was decreased after knocking down gm9795; e. Interference efficiency of siRNA-gm9795 in PA model; f. In PA model, the mRNA expression of TNF $\alpha$  was decreased after knocking down

gm9795;g. In PA model, the mRNA expression of IL-6 was decreased after knocking down gm9795; h. In PA model, the mRNA expression of IL-1 $\beta$  was decreased after knocking down gm9795; i. In MCD+LPS model, the protein expression of inflammation factors was decreased after knocking down gm9795; j. In PA model, the protein expression of inflammation factors was decreased after knocking down gm9795; (\*:P<0.05, \*\*P<0.01\*\*\*P<0.001).




**Figure 5**

LncRNA-gm9795 significantly increased the expression of inflammatory factors in NASH: a. The efficiency of gm9795 overexpression plasmid; b. The mRNA expression of TNF $\alpha$  increased after the overexpression of gm9795;c. The mRNA expression of IL-6 increased after the overexpression of gm9795; d.The mRNA expression of IL-1 $\beta$  increased after the overexpression of gm9795;e. The protein expression of inflammatory factors increased after the overexpression of gm9795 (\*:P<0.05, \*\*P<0.01\*\*\*P<0.001).



**Figure 6**

LncRNA-gm9795 significantly increased the expression of inflammation factors in NASH through NF- $\kappa$ B/JNK pathway. a. The expression of NF- $\kappa$ B/JNK signaling proteins was decreased after gm9795 knockout in MCD+LPS model; b. The expression of NF- $\kappa$ B/JNK signaling proteins was decreased after gm9795 knockout in PA model; c. The expression of NF- $\kappa$ B/JNK signaling proteins was increased after the overexpression of gm9795;



**Figure 7**

LncRNA-gm9795 activates ERS: a. The mRNA expression of IRE1 $\alpha$  was decreased after gm9795 knockout in MCD+LPS model; b. The mRNA expression of BIP was decreased after gm9795 knockout in MCD+LPS model; c. The mRNA expression of CHOP had no significant change after gm9795 knockout in MCD+LPS model; d. The mRNA expression of IRE1 $\alpha$  was decreased after gm9795 knockout in PA model; e. The mRNA expression of BIP was decreased after gm9795 knockout in PA model; f. The mRNA

expression of CHOP had no significant change after gm9795 knockout in PA model; g. The protein expression of ERS was decreased after gm9795 knockout in MCD+LPS model; h. The protein expression of ERS was decreased after gm9795 knockout in PA models; (NS: Nonsense, \*: $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.001$ )




Figure 8

LncRNA-gm9795 activated NF-kB/JNK pathway through ERS:a. The NF-kB/JNK pathway was activated by introducing endoplasmic reticulum stress agonists after gm9795 was knocked out in MCD+LPS model; b. The NF-kB/JNK pathway was activated by introducing endoplasmic reticulum stress agonists after gm9795 was knocked out in PA model; c. The NF-kB/JNK pathway was inhibited by introducing endoplasmic reticulum stress inhibitor after gm9795 was overexpressed